Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases
Status:
Recruiting
Trial end date:
2023-12-09
Target enrollment:
Participant gender:
Summary
If an abbreviated HBP protocol liver MR with gadobenate dimeglumine is shown clinically
comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic
metastasis from colorectal cancer, its use will save time, cost, and patients' effort.
Phase:
Phase 4
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Bracco Diagnostics, Inc National Cancer Institute (NCI)